Angiotensin II receptor antagonists in combination with calcium channel blockers;Antagonistas de los receptores de la angiotensina II en combinación con antagonistas del calcio

Hipertension y Riesgo Vascular

Volumn 27, Issue SUPPL. 2, 2010, Pages 16-21

  Gorostidi, M ^a   De la Sierra, A ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT;

ARTICLE;

EID: 79958758263     PISSN: 18891837     EISSN: 19894805     Source Type: Journal    
DOI: 10.1016/S1889-1837(10)70015-5     Document Type: Article

References (42)

1. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
2. He F.J., MacGregor G.A. Blood pressure is the most important cause of death and disability in the world. Eur Heart J 2007, 9(Suppl B):B23-B28.
3. Banegas J.R., Rodríguez Artalejo F., Cruz J.J., Guallar P., Rey J. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension 1998, 32:998-1002.
4. Banegas J.R., Rodríguez-Artalejo F., Ruilope L.M., Graciani A., Luque M., Cruz J.J., García-Robles R., Tamargo J., Rey-Calero J. Hypertension magnitude and management in the elderly population of Spain. J Hypertens 2002, 20:2157-2164.
5. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913. Prospective Studies Collaboration.
6. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827-838.
7. Staessen J.A., Gasowski J., Wang J.G., Thijs L., Hond E.D., Boissel J.P., et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355:865-872.
8. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialists' Collaboration.
9. Wolf-Maier K., Cooper R.S., Banegas J.R., Giampaoli S., Hense H.W., Joffres M., et al. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA 2003, 289:2363-2369.
10. Kearney P.M., Whelton M., Reynolds K., Whelton P.K., He J. World-wide prevalence of hypertension: a systematic review. J Hypertens 2004, 22:11-19.
11. Llisterri J.L., Rodríguez-Roca G., Alonso F.J., Banegas J.R., González-Segura D., Lou S., et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2006. Med Clin (Barc) 2008, 130:681-687.
12. Banegas J.R., Segura J., Ruilope L.M., Luque M., García-Robles R., Campo C., et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004, 43:1338-1344.
13. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007, 25:1105-1187.
14. De la Sierra A., Gorostidi M., Marín R., Redon J., Banegas J.R., Armario P., et al. Evaluación y tratamiento de la hipertensión arterial en España, 2008. Med Clin (Barc) 2008, 131:104-116.
15. De la Sierra A. Blood pressure control in the hypertensive population. What else the doctor can do?. J Hypertens 2010, 28:1129-1130.
16. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427-1431.
17. Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulfield M.J., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158.
18. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection. Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003, 289:2560-2572.
19. De la Sierra A. Combinations as a first step therapy in hypertension. Curr Hypertens Rep 2007, 9:251-252.
20. Kjieldsen S.E., Aksnes T.A., De la Sierra A., Ruilope L.M. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptors blockers combination for hypertension. Therapy 2007, 4:31-40.
21. Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
22. Jamerson K., Weber M.A., Bakris G.L., Dahlöf B., Pitt B., Shi V., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428. for the ACCOMPLISH trial investigators.
23. Bakris G.L., Sarafidis P.A., Weir M.R., Dahlöf B., Pitt B., Jamerson K., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173-1181. ACCOMPLISH Trial investigators.
24. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003. LIFE Study Group.
25. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003, 21:875-886. SCOPE Study Group.
26. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parking H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. RENAAL Study Investigators.
27. Kaneshiro Y., Ichihara A., Sakoda M., Kurauchi-Mito A., Kinouchi K., Itoh H. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009, 32:51-58.
28. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006, 20:787-794.
29. Sanford M., Keam S.J. Olmesartan medoxomil/amlodipine. Drugs 2009, 69:717-729.
30. Mason R.P., Marche P., Hintze T.H. Novel vascular biology of thirdgeneration L-type calcium channel antagonists. Arterioscler Thromb Vasc Biol 2003, 23:2155-2163.
31. Sales V.L., Sukhova G.K., Lopez-Ilasaca M.A., Libby P., Dzau V.J., Pratt R.E. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 2005, 112:3328-3336.
32. Bakris G., Molitch M., Hewkin A., Kipnes M., Sarafidis P., Fakouhi K., et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006, 29:2592-2597. for the STAR Investigators.
33. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010, 362:1477-1490. The Navigator Study Group.
34. De la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009, 23:503-511.
35. Chrysant S.G., Melino M., Karki S., Lee J., Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, doubleblind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008, 30:587-604.
36. Chrysant S.G., Oparil S., Melino M., Karki S., Lee J., Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009, 11:475-482.
37. Oparil S., Lee J., Karki S., Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol 2009, 54:427-436.
38. Barrios V., Brommer P., Haag U., Calderón A., Escobar C. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009, 29:427-439.
39. Chrysant S.G., Lee J., Melino M., Karki S., Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 2010, Feb 18. [Epub ahead of print].
40. Fogari R., Malamani G., Corradi L., Mugellini A., Preti P., Zoppi A., Derosa G. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Adv Ther 2010, 27:48-55.
41. Ogawa H., Kim-Mitsuyama S., Jinnouchi T., Matsui K., Arakawa K. Rationale, design and patient baseline characteristics of Olme-Sartan and Calcium Antagonists Randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients. Hypertens Res 2009, 32:575-580.
42. Ogihara T., Saruta T., Rakugi H., Shimamoto K., Ito S., Matsuoka H., et al. Rationale, study design and implementation of the COLM study: the Combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009, 32:163-167. COLM study investigators.